Eli Lilly and Company (LLY) Market Cap & Valuation Ratios
Eli Lilly and Company (LLY) has a market cap of $1.20T, a trailing P/E of 42.7 and a price-to-sales ratio of 15.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LLYEli Lilly and CompanyFollow LLY — free
—
Price chart with a free account
- Market cap
- 1.20T
- P/E TTM
- 42.7
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LLY | 1199 | 42.7 | 15.6 | 43.5 | 1.5% | +50% | 41% | 27% |
| JNJ | 635 | 40.0 | 6.7 | 24.7 | 3.2% | +8% | 19% | 16% |
| ABBV | 505 | 80.7 | 8.8 | 23.0 | 3.6% | +10% | 26% | 21% |
| MRK | 358 | 115.3 | 6.1 | 28.1 | 4.5% | +5% | 12% | 5% |
| AZN | 274 | 25.7 | 4.9 | 14.7 | 4.3% | +9% | 23% | 16% |
| AMGN | 237 | 27.3 | 7.4 | 17.4 | 4.3% | +9% | 30% | 18% |
| GILD | 193 | — | 7.1 | 823.4 | 6.7% | +6% | -8% | -7% |
| PFE | 171 | 39.5 | 3.5 | 16.8 | 6.4% | -0.2% | 11% | 4% |
| BMY | 126 | 13.5 | 3.2 | 9.4 | 9.1% | +3% | 28% | 19% |
| TEVA | 46 | — | 3.4 | 22.7 | 2.9% | +4% | 9% | 7% |
| ONC | 43 | 67.6 | 6.5 | 36.9 | 3.1% | +34% | 15% | 35% |
| Median of these 10 | 39.8 | 6.3 | 22.8 | 4.3% | +7% | 17% | 16% |
P/E 42.7 vs. a peer median of 39.8; EV/Sales 15.6 vs. 6.3. LLY's own P/E sits at the 23rd percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesGILD and TEVA have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Eli Lilly and Company — questions
- What is Eli Lilly and Company's market cap?
- $1.20T.
- What is Eli Lilly and Company's P/E ratio?
- 42.7 on trailing twelve-month earnings to 2026-06-30.
- What is Eli Lilly and Company's price-to-sales ratio?
- 15.1.
Every figure on this page comes from Eli Lilly and Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.